Last reviewed · How we verify

Medicis Global Service Corporation — Portfolio Competitive Intelligence Brief

Medicis Global Service Corporation pipeline: 1 marketed, 0 filed, 1 Phase 3, 2 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 1 Phase 3 2 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Minocycline, Clindamycin, Tretinoin, Benzoyl Peroxide Minocycline, Clindamycin, Tretinoin, Benzoyl Peroxide marketed
Product 55394 Product 55394 phase 3 topical retinoid Dermatology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Galderma R&D · 1 shared drug class
  2. Sol-Gel Technologies, Ltd. · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Medicis Global Service Corporation:

Cite this brief

Drug Landscape (2026). Medicis Global Service Corporation — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/medicis-global-service-corporation. Accessed 2026-05-17.

Related